secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031351
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics reports Q3 net loss of $6.1M; appoints Jill Howe as CFO
--------------------------------------------------------------------------------

- Net loss attributable to Lineage of $6.1M ($0.04/share) vs $7.8M ($0.05/share) in Q3 2021.
- Total revenue $3.0M, up from $2.3M YoY, driven by Roche collaboration revenue.
- Cash, equivalents, and marketable securities $66.4M as of Sep 30, 2022; expected runway into Q3 2024.
- Appointed Jill Howe as CFO effective Nov 14, 2022; she has 20+ years biotech finance experience.
- Received notice of allowance for two patents covering directed differentiation methods for RPE and OPC cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/0001493152-22-031351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer